Donaldson price target raised to $69 from $66 at Baird

Baird analyst Richard Eastman raised the firm’s price target on Donaldson to $69 from $66 and keeps an Outperform rating on the shares. The analyst said we continue to favor Donaldson for its defensive profile as uncertainty persists, and reasonable valuation. New Life Sciences segment reflects a multi-year growth diversification effort.